Document Detail


Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
MedLine Citation:
PMID:  23121448     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Ranolazine is a novel antianginal and anti-ischemic agent, that, unlike other available antianginal drugs in the United States (beta-blockers, organic nitrates, and calcium channel blockers), has no significant effect on either heart rate or blood pressure. Its exact mechanism of action is unknown. Ranolazine does increase electrocardiographic QTc interval in a dose-related manner, but at therapeutic doses it has no proarrhythmic effects. Ranolazine (ER) at doses of 500 and 1,000 mg twice daily is currently approved for the treatment of angina pectoris either as monotherapy or added to beta-blockers, nitrates, and calcium channel blockers. Ranolazine (ER) is currently not approved for the treatment of unstable angina, silent ischemia, or cardiac arrhythmias. The most common adverse effects reported in clinical trials during ranolazine (ER) treatment are dizziness, headaches, constipation, and nausea.
AREAS COVERED: Recent changes in ranolazine (ER) labeling have led to its increased use for treating patients with ischemic heart disease. This review addresses its appropriate use. All publications were reviewed and those relevant were included.
EXPERT OPINION: Ranolazine (ER) is an effective antianginal and anti-ischemic agent, but I restrict its use to treat patients with stable angina pectoris.
Authors:
Udho Thadani
Related Documents :
10449688 - Amiodarone protects cardiac myocytes against oxidative injury by its free radical scave...
24706498 - Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infa...
18701048 - Human thioredoxin exerts cardioprotective effect and attenuates reperfusion injury in r...
9812748 - Diacetylamethystoidin a protects isolated working rat heart against myocardial reperfus...
6969568 - A follow-up study of coronary bypass patients without patent grafts.
21414568 - Speckle-tracking echocardiography for predicting outcome in chronic aortic regurgitatio...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-11-02
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-12     Completed Date:  2013-04-18     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2555-63     Citation Subset:  IM    
Affiliation:
University of Oklahoma Health Sciences Center, OU Medical Center, Oklahoma City, OK 73104, USA. Udho-Thadani@ouhsc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetanilides / pharmacology,  therapeutic use*
Cardiotonic Agents / pharmacology,  therapeutic use*
Humans
Myocardial Ischemia / drug therapy*
Piperazines / pharmacology,  therapeutic use*
Product Surveillance, Postmarketing
Sodium Channel Blockers / pharmacology,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Acetanilides; 0/Cardiotonic Agents; 0/Piperazines; 0/Sodium Channel Blockers; 110445-25-5/ranolazine
Comments/Corrections
Comment In:
Expert Opin Pharmacother. 2012 Dec;13(17):2429-32   [PMID:  23121536 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ablation of the cellular prion protein, PrPC, specifically on follicular dendritic cells has no effe...
Next Document:  Vitamin D status, left ventricular geometric abnormalities and cardiovascular disease.